Carfilzomib

Generic Name: Carfilzomib

Brand Names: Kyprolis

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₇N_₅O_₇

CAS Number: 868540-17-4

Unique Ingredient Identifier: 72X6E3J5AR

Background: Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.

Indication: Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Associated Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Associated Therapies: -

Clinical Trials

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

Phase 2

Completed

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: Carfilzomib
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2015-07-08

Last Posted Date: 2019-02-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT02491359

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 2 locations

Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation

Phase 2

Completed

Conditions: Lung Transplant Rejection

Interventions: Drug: Carfilzomib

First Posted Date: 2015-06-18

Last Posted Date: 2022-04-25

Lead Sponsor: John F. McDyer, MD

Target Recruit Count: 22

Registration Number: NCT02474927

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

B-Cell Targeted Carfilzomib Desensitization

Phase 1

Conditions: Transplants and Implants

Interventions: Drug: Carfilzomib
Drug: Rituximab

First Posted Date: 2015-05-13

Last Posted Date: 2020-06-30

Lead Sponsor: E. Steve Woodle

Target Recruit Count: 32

Registration Number: NCT02442648

Locations: 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Smoldering Multiple Myeloma

Interventions: Drug: carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Melphalan

First Posted Date: 2015-04-14

Last Posted Date: 2022-09-10

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 90

Registration Number: NCT02415413

Locations: 🇪🇸
Hospital Clínico San Carlos, Madrid, Spain
🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

and more 13 locations

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2015-04-09

Last Posted Date: 2022-09-23

Lead Sponsor: Amgen

Target Recruit Count: 478

Registration Number: NCT02412878

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom
🇺🇸
Blood and Cancer Center of East Texas, Tyler, Texas, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

and more 3 locations

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Dexamethasone
Drug: Pomalidomide
Drug: Bortezomib
Drug: Lenalidomide
Drug: Daratumumab
Drug: Carfilzomib
Drug: Ixazomib
Drug: Belantamab Mafodotin
Drug: Mezigdomide
Drug: Elotuzumab
Drug: Clarithromycin

First Posted Date: 2015-01-21

Last Posted Date: 2024-05-07

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 300

Registration Number: NCT02343042

Locations: 🇺🇸
Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States

and more 21 locations

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Phase 1

Completed

Conditions: T-cell Lymphomas
Relapsed or Refractory

Interventions: Drug: Carfilzomib
Drug: Romidepsin
Drug: Lenalidomide

First Posted Date: 2015-01-19

Last Posted Date: 2024-04-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 27

Registration Number: NCT02341014

Locations: 🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 3 locations

Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2015-01-12

Last Posted Date: 2020-11-06

Lead Sponsor: Amgen

Target Recruit Count: 107

Registration Number: NCT02335983

Locations: 🇺🇸
Saint Francis Hospital Cancer Center, Greenville, South Carolina, United States
🇺🇸
Greenville Health System, Greenville, South Carolina, United States
🇺🇸
Morton Coleman, MD, New York, New York, United States

and more 27 locations

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Biological: Isatuximab
Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2015-01-07

Last Posted Date: 2024-04-01

Lead Sponsor: Thomas Martin, MD

Target Recruit Count: 83

Registration Number: NCT02332850

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 3 locations

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Phase 2

Completed

Conditions: Neuroendocrine Cancer

Interventions: Drug: Carfilzomib

First Posted Date: 2014-12-17

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 62

Registration Number: NCT02318784

Locations: 🇺🇸
Oncology Hematology Care, INC., Cincinnati, Ohio, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists - North, Saint Petersburg, Florida, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy